Above all, we make a difference.
Home > Breast Cancer Information > Metastatic Breast Cancer > Metastatic Breast Cancer References

Metastatic Breast Cancer References

  1. Surveillance Research Program, National Cancer Institute. SEERExplorer. Breast cancer – SEER relative survival rates by time since diagnosis, 2000-2020, by stage at diagnosis, female, all races/ethnicities, all ages, distant. Accessed on April 23, 2024. https://seer.cancer.gov/explorer/, 2024.
  2. Mariotto AB, Etzioni R, Hurlbert M, PenberthyL, Mayer M. Estimation of the number of women living with metastatic breast cancer in the United States. Cancer Epidemiol Biomarkers Prev. 26(6):809-815, 2017.
  3. Surveillance Research Program, National Cancer Institute. SEERExplorer. Breast cancer- Stage distribution of SEER incidence cases, 2012-2021 by sex, all races/ethnicities, all ages. Accessed on April 18, 2024. https://seer.cancer.gov/explorer/, 2024.
  4. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Breast cancer. V.5.2024. http://www.nccn.org, 2024.
  5. Rugo HS, Rumble RB, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. J Clin Oncol. 34(25):3069-103, 2016.
  6. Burstein HJ, DeMichele A, Somerfield MR, et al. for the Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels. Testing for ESR1 mutations to guide therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 41(18):3423-3425, 2023.
  7. Bidard FC, Kaklamani VG, Neven P, et al. Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD Trial. J Clin Oncol. 40(28):3246-3256, 2022.
  8. U.S. Food and Drug Administration. Elacestrant (Orserdu) labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf, 2023.
  9. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 375(18):1738-1748, 2016.
  10. Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 35(25):2875-2884, 2017.
  11. Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 379(20):1926-1936, 2018.
  12. Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 36(24):2465-2472, 2018.
  13. Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 381(4):307-316, 2019.
  14. Howie LJ, Singh H, Bloomquist E, et al. Outcomes of older women with hormone receptor-positive, human epidermal growth factor receptor-negative metastatic breast cancer treated with a CDK4/6 inhibitor and an aromatase inhibitor: an FDA pooled analysis. J Clin Oncol. 37(36):3475-3483, 2019.
  15. Gao JJ, Cheng J, Bloomquist E, et al. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Lancet Oncol. 21(2):250-260, 2020.
  16. Slamon DJ, Neven P, Chia S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol. 32(8):1015-1024, 2021.
  17. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 386(10):942-950, 2022.
  18. Xu B, Hu X, Li W, et al. Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4. Eur J Cancer. 175:236-245, 2022.
  19. Slamon DJ, Diéras V, Rugo HS, et al. Overall survival with palbociclib plus letrozole in advanced breast cancer. J Clin Oncol. 42(9):994-1000, 2024.
  20. U.S. Food and Drug Administration (FDA). Verzenio (abemaciclib) labeling information, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208716s006s007s008lbl.pdf, 2021.
  21. U.S. Food and Drug Administration. Ibrance (palbociclib) labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/207103s015lbl.pdf, 2022.
  22. U.S. Food and Drug Administration. Kisqali (ribociclib) labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209092s019lbl.pdf, 2024.
  23. André F, Ciruelos E, Rubovszky G, et al. for the SOLAR-1 Study Group. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 380(20):1929-1940, 2019.
  24. Turner NC, Oliveira M, Howell SJ, et al. for the CAPItello-291 Study Group. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 388(22):2058-2070, 2023.
  25. U.S. Food and Drug Administration. Piqray (alpelisib) labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212526s006lbl.pdf, 2022.
  26. U.S. Food and Drug Administration (FDA). Capivasertib (Truqap) labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf, 2023.
  27. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone receptor-positive advanced breast cancer. N Engl J Med. 366(6):520-9, 2012.
  28. Bachelot T, Bourgier C, Cropet C, et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 30(22):2718-24, 2012.
  29. U.S. Food and Drug Administration. Everolimus (Afinitor) labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023,022334s051lbl.pdf, 2022.
  30. Rakha EA, Pinder SE, Bartlett JM, et al. for the National Coordinating Committee for Breast Pathology. Updated UK recommendations for HER2 assessment in breast cancer. J Clin Pathol. 68(2):93-9, 2015.
  31. Joe BN. Clinical features, diagnosis, and staging of newly diagnosed breast cancer. In: UpToDate. Burstein H, Vora SR (eds.). Waltham, MA: UpToDate, 2024.
  32. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344: 783-92, 2001.
  33. Andersson M, Lidbrink E, Bjerre K, et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol. 29(3):264-71, 2011.
  34. Gelmon KA, Boyle FM, Kaufman B, et al. Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast Cancer: final results of NCIC CTG MA.31. J Clin Oncol. 33(14):1574-83, 2015.
  35. Urruticoechea A, Rizwanullah M, Im SA, et al. Randomized phase III trial of trastuzumab plus capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who experienced disease progression during or after trastuzumab-based therapy. J Clin Oncol. 35(26):3030-3038, 2017.
  36. Swain SM, Miles D, Kim SB, et al. for the CLEOPATRA study group. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 21(4):519-530, 2020.
  37. Rugo HS, Im SA, Cardoso F, et al. for the SOPHIA Study Group. Margetuximab versus trastuzumab in patients with previously treated HER2-positive advanced breast cancer (SOPHIA): final overall survival results from a randomized phase 3 trial. J Clin Oncol. 41(2):198-205, 2023.
  38. U.S. Food and Drug Administration (FDA). Margenza (margetuximab-cmkb) labeling information, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf, 2020.
  39. Verma S, Miles D, Gianni L, et al. for the EMILIA Study Group. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 367(19):1783-91, 2012.
  40. U.S. Food and Drug Administration. Kadcyla (ado-trastuzumab emtansine) labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf, 2020.
  41. Modi S, Saura C, Yamashita T, et al. for the DESTINY-Breast01 Investigators. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 382(7):610-621, 2020.
  42. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 401(10371):105-117, 2023.
  43. Cortés J, Kim SB, Chung WP, et al. for the for the DESTINY-Breast03 Trial Investigators. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 386(12):1143-54, 2022.
  44. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. Engl J Med. 387(1):9-20, 2022.
  45. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 355(26):2733-43, 2006.
  46. Burstein HJ, Cirrincione CT, Barry WT, et al. Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). J Clin Oncol. 32(35):3959-66, 2014.
  47. Blackwell KL, Burstein HJ, Storniolo AM, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 30(21):2585-92, 2012.
  48. Guan Z, Xu B, DeSilvio ML, et al. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol. 31(16):1947-53, 2013.
  49. Awada A, Colomer R, Inoue K, et al. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial. JAMA Oncol. 2(12):1557-1564, 2016.
  50. Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med. 382(7):597-609, 2020.
  51. Curigliano G, Mueller V, Borges V, et al. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol. 33(3):321-329, 2022.
  52. Lin NU, Murthy RK, Abramson V, et al. Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial. JAMA Oncol. 9(2):197-205, 2023.
  53. Sutherland S, Ashley S, Miles D, et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience. Br J Cancer. 102(6):995-1002, 2010.
  54. Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 14(1):64-71, 2013.
  55. Petrelli F, Ghidini M, Lonati V, et al. The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysis. Eur J Cancer. 84:141-148, 2017.
  56. Freedman RA, Gelman RS, Anders CK, et al. for the Translational Breast Cancer Research Consortium. TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol. 37(13):1081-1089, 2019.
  57. U.S. Food and Drug Administration (FDA). Tukysa labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf, 2023.
  58. U.S. Food and Drug Administration (FDA). Nerlynx labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/208051s009lbl.pdf, 2021.
  59. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 377(6):523-533, 2017.
  60. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 379(8):753-763, 2018.
  61. Robson ME, Im SA, Senkus E, et al. OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Eur J Cancer. 184:39-47, 2023.
  62. U.S. Food and Drug Administration (FDA). Talzenna (talazoparib) labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211651s008lbl.pdf, 2021.
  63. U.S. Food and Drug Administration (FDA). Lynparza (olaparib) labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208558s021lbl.pdf, 2022.
  64. Winer EP, Lipatov O, Im SA, et al. for the KEYNOTE-119 investigators. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncol. 22(4):499-511, 2021.
  65. Cortes J, Rugo HS, Cescon DW, et al. for the KEYNOTE-355 Investigators. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 387(3):217-226, 2022.
  66. U.S. Food and Drug Administration (FDA). Keytruda (pembrolizumab) labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s110lbl.pdf, 2022.
  67. Bardia A, Mayer IA, Vahdat LT, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 380(8):741-751, 2019.
  68. Rugo HS, Bardia A, Marmé F, et al. Sacituzumab govitecan in hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 40(29):3365-3376, 2022.
  69. Bardia A, Rugo HS, Tolaney SM, et al. Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression. J Clin Oncol. 42(15):1738-1744, 2024.
  70. U.S. Food and Drug Administration (FDA). Sacituzumab govitecan (Trodelvy) labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf, 2023.
  71. National Academy of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. Washington, D.C.: The National Academies Press, 2017.
  72. Braun IM, Bohlke K, Abrams DI, et al. Cannabis and cannabinoids in adults with cancer: ASCO guideline. J Clin Oncol. 42(13):1575-1593, 2024.
  73. Azizoddin DR, Cohn AM, Ulahannan SV, et al. Cannabis use among adults undergoing cancer treatment. Cancer. 129(21):3498-3508, 2023.
  74. Grimison P, Mersiades A, Kirby A, et al. Oral cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: final results of a randomized, placebo-controlled, phase II/III trial. J Clin Oncol. 42(34):4040-4050, 2024.
  75. American Cancer Society. Diarrhea. https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/stool-or-urine-changes/diarrhea.html, 2024.
  76. Macaron C and Kamath S. Management of acute chemotherapy-related diarrhea, in UpToDate (Drews RE and Vora SR, eds.). Waltham, MA: UpToDate, 2024.
  77. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Cancer-related fatigue. V.2.2024. http://www.nccn.org, 2024.
  78. Headley JA, Ownby KK, John LD. The effect of seated exercise on fatigue and quality of life in women with advanced breast cancer. Oncol Nurs Forum. 31(5):977-83, 2004.
  79. National Cancer Institute. Chemotherapy and you: support for people with cancer. https://www.cancer.gov/publications/patient-education/chemo-and-you, 2024.
  80. Escalante CP. Cancer-related fatigue: treatment. In: UpToDate (Hesketh PJ, Ganz PA, Vora SR, eds.). Waltham, MA: UpToDate, 2024.
  81. Aapro M, Leonard RC, Barnadas A, et al. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol. 26(4):592-8, 2008.
  82. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol. 26(1):132-49, 2008.
  83. Chavez-MacGregor M, Zhao H, Fang S, Srokowski TP, Hortobagyi GN, Giordano SH. Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: a Surveillance, Epidemiology, and End Results-Medicare study. Cancer. 117(16):3641-9, 2011.
  84. U.S. Food and Drug Administration. Epogen (epoetin alfa) labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103234s5363s5366lbl.pdf, 2017.
  85. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Hematopoietic growth factors. V.3.2024. http://www.nccn.org, 2024.
  86. Mao JJ, Ismalia N, Bao T, et al. Integrative medicine for pain management in oncology: Society for Integrative Oncology-ASCO guideline. J Clin Oncol. 40:3998-4024, 2022.
  87. Liu SV and Russell CA. Chapter 82: Medical treatment for bone metastases, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
  88. O’Carrigan B, Wong MH, Willson ML, Stockler MR, Pavlakis N, Goodwin A. Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev. 10(10):CD003474, 2017.
  89. Jackson C, Freeman ALJ, Szlamka Z, Spiegelhalter DJ. The adverse effects of bisphosphonates in breast cancer: A systematic review and network meta-analysis. PLoS One. 16(2):e0246441, 2021.
  90. Van Poznak CH, Unger JM, Darke AK, et al. Association of osteonecrosis of the jaw with zoledronic acid treatment for bone metastases in patients with cancer. JAMA Oncol. 7(2):246-254, 2021.
  91. Van Poznak C, Somerfield MR, Barlow WE, et al. Role of bone-modifying agents in metastatic breast cancer: an American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update. J Clin Oncol. 35(35):3978-3986, 2017.
  92. Bardia A, Jhaveri K, Im SA, et al. for the TROPION-Breast01 Investigators. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01. J Clin Oncol. 43(3):285-296. 2025.
  93. Tung NM, Robson ME, Ventz S, et al. TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol. 38(36):4274-4282, 2020.
  94. U.S. Food and Drug Administration. Avastin (bevacizumab) information. https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm193900.htm, 2018.
  95. Cristofanelli M, Budd GT, Ellis MJ, Stopeck AS, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 351(8):781-91, 2004.
  96. Bidard FC, Peeters DJ, Fehm T, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 15(4):406-14, 2014.
  97. Smerage JB, Barlow WE, Hortobagyi GN, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 32(31):3483-9, 2014.
  98. Henry NL, Somerfield MR, Dayao Z, et al. Biomarkers for systemic therapy in metastatic breast cancer: ASCO guideline update. J Clin Oncol. 40(27):3205-3221, 2022.
  99. Chia S. Prognostic and predictive factors in metastatic breast cancer, in UpToDate (Burstein HJ, Vora SR, eds.). Waltham, MA: UpToDate, 2024.
  100. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 368(13):1199-209, 2013.
  101. Visvanathan K, Fackler MS, Zhang Z, et al. Monitoring of serum DNA methylation as an early independent marker of response and survival in metastatic breast cancer: TBCRC 005 prospective biomarker study. J Clin Oncol. 35(7):751-758, 2017.
  102. Stover DG, Parsons HA, Ha G, et al. Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer. J Clin Oncol. 36(6):543-553, 2018.
  103. Dickinson K, Sharma A, Agnihotram RV, et al. Circulating tumor DNA and survival in metastatic breast cancer: a systematic review and meta-analysis. JAMA Netw Open. 7(9):e2431722, 2024.
  104. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Palliative care. V.1.2024. http://www.nccn.org, 2024.
  105. Smith CB, Phillips T, Smith TJ. Using the new ASCO clinical practice guideline for palliative care concurrent with oncology care using the TEAM approach. Am Soc Clin Oncol Educ Book. 37:714-723, 2017.
  106. National Cancer Institute. Support for people with cancer: Cancer pain control. https://www.cancer.gov/publications/patient-education/pain-control, 2019.
  107. American Cancer Society. Developing a pain control plan. https://www.cancer.org/cancer/managing-cancer/side-effects/pain/cancer-pain/developing-a-pain-control-plan.html, 2024.
  108. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology: Adult cancer pain V.2.2024. http://www.nccn.org/, 2024.
  109. Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 14(Suppl 4): iv45–iv54, 2012.
  110. Teoh D, Smith TJ, Song M, Spirtos NM. Care after chemotherapy: peripheral neuropathy, cannabis for symptom control, and mindfulness. Am Soc Clin Oncol Educ Book. 469-479, 2018.
  111. Brady BL, Lucci M, Wilson K, et al. Chemotherapy-induced peripheral neuropathy in metastatic breast cancer patients initiating intravenous paclitaxel/nab-paclitaxel. Am J Manag Care. 27(1 Spec. No.):SP37-SP43, 2021.
  112. Paice JA, Bohlke K, Barton D, et al. Use of opioids for adults with pain from cancer or cancer treatment: ASCO guideline. J Clin Oncol. 41:914-930, 2022.
  113. Scarborough BM, Smith CB. Optimal pain management for patients with cancer in the modern era. CA Cancer J Clin 68(3):182-196, 2018.
  114. Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: A clinical review. JAMA. 313:2474-83, 2015.
  115. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: A systematic review and meta-analysis. JAMA. 313:2456-73, 2015.
  116. Strouse T. Cannabinoids in cancer treatment settings. J Commun Support Oncol. 14:1-5, 2016.
  117. Nugent SM, Morasco BJ, O’Neil ME, et al. The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Intern Med. 167(5):319-31, 2017.
  118. Mücke M, Phillips T, Radbruch L, et al. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 3(3):CD012182, 2018.
  119. Ghasemiesfe M, Barrow B, Leonard S, Keyhani S, Korenstein D. Association between marijuana use and risk of cancer: a systematic review and meta-analysis. JAMA Netw Open. 2(11):e1916318, 2019.
  120. Steele G, Arneson T, Zylla D. A comprehensive review of cannabis in patients with cancer: Availability in the USA, general efficacy, and safety. Curr Oncol Rep 21(1):10, 2019.
  121. U.S. Department of Health and Human Services and Centers for Medicare & Medicaid Services. Hospice care. https://www.medicare.gov/coverage/hospice-care, 2024.
  122. Goodwin PJ. Support groups in advanced breast cancer. Cancer. 104(11 Suppl):2596-601, 2005.
  123. Jones SM, LaCroix AZ, Li W, et al. Depression and quality of life before and after breast cancer diagnosis in older women from the Women’s Health Initiative. J Cancer Surviv. 9(4):620-9, 2015.
  124. National Cancer Institute. Depression. https://www.cancer.gov/about-cancer/coping/feelings/depression-pdq, 2024.
  125. Hamer J, McDonald R, Zhang L, et al. Quality of life (QOL) and symptom burden (SB) in patients with breast cancer. Support Care Cancer. 25(2):409-419, 2017.
  126. Cheng MJ and Smith TJ. Chapter 73: Palliative care in breast cancer, in Harris JR, Lippman ME, Morrow M, Osborne CK. Diseases of the Breast, 5th edition. Lippincott Williams and Wilkins, 2014.
  127. Reblin M, Baucom BRW, Clayton MF, et al. Communication of emotion in home hospice cancer care: Implications for spouse caregiver depression into bereavement. Psychooncology. 28(5):1102-1109, 2019.
  128. U.S. Food and Drug Administration. Inavolisib (Itovebi) labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/219249s001lbl.pdf, 2024.
  129. Turner NC, Im SA, Saura C, et al. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. N Engl J Med. 391(17):1584-1596, 2024.
  130. Harbeck N, Ciruelos E, Jerusalem G, et al for the DESTINY-Breast12 study group. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. Nat Med. 30(12):3717-3727, 2024.
  131. André F, Cortés J, Curigliano G, et al. A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases. Ann Oncol. 35(12):1169-1180, 2024.
  132. Bardia A, Hu X, Dent R, et al. for the DESTINY-Breast06 Trial Investigators. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. 391(22):2110-2122, 2024.
  133. Jhaveri KL, Neven P, Casalnuovo ML, et al. for the EMBER-3 Study Group. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med. 2024 Dec 11 [Online ahead of print].
  134. U.S. Food and Drug Administration. Datopotamab deruxtecan (Datroway) labeling information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761394s000lbl.pdf, 2025.

Updated 02/21/25

This content is regularly reviewed by an expert panel including researchers, practicing clinicians and patient advocates.

TOOLS & RESOURCES

PDF

Fact Sheet

Support After a Breast Cancer Diagnosis

PDF

Fact Sheet

What is Breast Cancer?